Dima Shulkin: Comparing HALP and PIV for Mortality Prediction in ACS
Dima Shulkin, Co-Founder and CTO at RobotDreams GmbH, shared a post on LinkedIn about a recent article by Azmi Eyiol, published in Journal of Clinical Medicine, adding:
“A new multicenter study in acute coronary syndrome puts two simple blood-based scores under the microscope: PIV, a combined immune-inflammation value, and HALP, a score built from hemoglobin, albumin, lymphocytes and platelets.
In 1.134 hospitalized patients, HALP predicted mortality better than PIV, with an AUROC of 0.722 versus 0.619, meaning it separated higher-risk from lower-risk patients more reliably.
The striking part is that this signal came from routine admission labs, not from a complex new test.”
Title: Pan-Immune-Inflammatory Value (PIV) and HALP Score as Independent Prognostic Indicators in Acute Coronary Syndrome Patients
Authors: Azmi Eyiol, Hatice Eyiol, Ahmet Yilmaz, Hasan Sari
Stay updated with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering